Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …

While pralatrexate (PDX) has been successfully developed for the treatment of T‐cell
lymphoma, the mechanistic basis for its T‐cell selectivity and acquired resistance remains …

Background: Pralatrexate (PDX) is a novel targeted antifolate that is designed to accumulate
preferentially in cancer cells. Pralatrexate selectively enters cells expressing RFC-1, a …

Introduction: Pralatrexate (PDX) is a dihydrofolate reductase inhibitor with high affinity for
reduced folate carrier 1 and folylpolyglutamate synthetase, resulting in extensive …

Folates are well known to be essential for many cellular processes, including cellular
proliferation. As a consequence, antifolates, the fraudulent mimics of folic acid, have been …

Abstract Abstract 1678 Poster Board I-704 Background The outcome of patients with PTCL is
poor and the majority of patients ultimately have refractory disease to a variety of agents …

Pralatrexate is an antifolate designed to be internalized more rapidly than other traditional
antifolates. Preclinical studies have demonstrated its superiority to methotrexate, and early …

Multiple myeloma (MM) is the second most common hematologic malignancy. While major
advances have been made in the disease, it is still incurable. Although antifolate-based …

Pralatrexate is a folate antagonist that selectively enters cells expressing reduced folate
carrier type 1 and competitively inhibits dihydrofolate reductase, leading to interruption of …

Background: Pralatrexate (PDX) is a novel targeted antifolate that is designed to accumulate
preferentially in cancer cells. Pralatrexate has demonstrated activity at a range of doses in …